Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Long axial field of view PET/CT in critically ill patients: lessons from a case report
Published in: Frontiers in Medicine
Access to document
10.3389/fmed.2023.1347791
document
The introduction of new long axial field of view (LAFOV) scanners is a major milestone in positron emission tomography/computed tomography (PET/CT) imaging. With these new systems a revolutionary reduction in scan time can be achieved, concurrently lowering tracer dose. Therefore, PET/CT has come within reach for groups of patients in whom PET/CT previously was undesirable. In this case report we discuss the procedure of a continuous bed motion (CBM) total-body [18F]FDG PET/CT scan in an intensive care patient. We emphasize the clinical and technical possibilities with this new...
J. H. van Snick, B. van Leer, M. W. N. Nijsten, J. Pillay, R. H. J. A. Slart, A. W. J. M. Glaudemans, N. D. van Rijsewijk
The first international network symposium on artificial intelligence and informatics in nuclear medicine: “The bright future of nuclear medicine is illuminated by artificial intelligence”
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-023-06507-7
document
Andor W J M Glaudemans, Rudi A J O Dierckx, Bart Scheerder, Wiro J Niessen, Jan Pruim, Dyah E O Dewi, Ronald J H Borra, Adriaan A Lammertsma, Charalampos Tsoumpas, Riemer H J A Slart
Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker? an early follow-up marker?
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-023-06459-y
document
PURPOSE: There is a need for early quantitative markers of potential treatment response in patients with hereditary transthyretin (ATTRv) amyloidosis to guide therapy. This study aims to evaluate changes in cardiac tracer uptake on bone scintigraphy in ATTRv amyloidosis patients on different treatments. METHODS: In this retrospective cohort study, outcomes of 20 patients treated with the transthyretin (TTR) gene silencer patisiran were compared to 12 patients treated with a TTR-stabilizer. Changes in NYHA class, cardiac biomarkers in serum, wall thickness, and diastolic parameters on echocardiography and NYHA class...
H S A Tingen, A Tubben, J Bijzet, M P van den Berg, P van der Meer, E J Houwerzijl, F L H Muntinghe, P A van der Zwaag, A W J M Glaudemans, M I F J Oerlemans, C Knackstedt, M Michels, A Hirsch, B P C Hazenberg, R H J A Slart, H L A Nienhuis
A systematic review for the evidence of recommendations and guidelines in hybrid nuclear cardiovascular imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-024-06597-x
document
OBJECTIVES: This study aimed to evaluate the level of evidence of expert recommendations and guidelines for clinical indications and procedurals in hybrid nuclear cardiovascular imaging. METHODS: From inception to August 2023, a PubMed literature analysis of the latest version of guidelines for clinical hybrid cardiovascular imaging techniques including SPECT(/CT), PET(/CT), and PET(/MRI) was performed in two categories: (1) for clinical indications for all-in primary diagnosis; subgroup in prognosis and therapy evaluation; and for (2) imaging procedurals. We surveyed to what degree these followed a standard methodology to collect...
Florent L Besson, Giorgio Treglia, Jan Bucerius, Constantinos Anagnostopoulos, Ronny R Buechel, Marc R Dweck, Paula A Erba, Oliver Gaemperli, Alessia Gimelli, Olivier Gheysens, Andor W J M Glaudemans, Gilbert Habib, Fabian Hyafil, Mark Lubberink, Christopher Rischpler, Antti Saraste, Riemer H J A Slart
Pharmacokinetic Analysis of [18F]FES PET in the Human Brain and Pituitary Gland.
Published in: Molecular Imaging and Biology
Access to document
10.1007/s11307-023-01880-z
document
PURPOSE: Estrogen receptors (ER) are implicated in psychiatric disorders. We assessed if ER availability in the human brain could be quantified using 16α-[ 18F]-fluoro-17β-estradiol ([ 18F]FES) positron emission tomography (PET). PROCEDURES: Seven post‑menopausal women underwent a dynamic [ 18F]FES PET scan with arterial blood sampling. A T1-weighted MRI was acquired for anatomical information. After one week, four subjects received a selective ER degrader (SERD), four hours before the PET scan. Pharmacokinetic analysis was performed using a metabolite-corrected plasma curve as the input function. The optimal kinetic model was...
Nafiseh Ghazanfari, Janine Doorduin, Chris W J van der Weijden, Antoon T M Willemsen, Andor W J M Glaudemans, Aren van Waarde, Rudi A J O Dierckx, Erik F J de Vries